Loading stock data…
$8.50+0.14 (+1.62%)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Prothena Corporation plc in the Healthcare sector is trading at $8.50 with a market capitalization of $466M. Wall Street consensus targets $21.40 (5 analysts), implying a +151.9% move over the next 12 months. The stock is currently near its 52-week low of $7.73, remaining 8.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.01M↓ | $51.08M↑ | $21,000↓ | $2.42M↓ | $4.42M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.69M↓ | $25.79M↑ | -$27.21M↑ | -$39.76M↑ | -$52.01M |
| Net Income | -$18.58M↓ | $32.72M↑ | -$21.59M↑ | -$36.54M↑ | -$125.77M |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...